ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Intracellular Aβ42 Sequestration by a Serine Protease Mitigates Neurotoxicity in a Drosophila Alzheimer's Disease Model.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Emerging evidence suggests that intraneuronal Aβ accumulation represents an early pathogenic event in Alzheimer's disease (AD), preceding extracellular plaque formation and neuroinflammatory responses. However, whether targeting intracellular Aβ can halt disease progression and how this can be achieved in vivo remain unknown. While investigating the brain transcriptional responses to Aβ pathology, we identify a neuroprotective role for the serine protease Yip7 in a Drosophila AD model. Neuronal overexpression of yip7 alleviates multiple Aβ42-induced deficits, including declines in locomotor activity, impaired proteostasis, increased brain aging and neuronal death, and shortened lifespan. Unlike canonical digestive proteases, Yip7 is not secreted but instead localized to the endosomal/lysosomal compartments via a putative transmembrane domain initially predicted as a signal peptide. Crucially, Yip7's neuroprotective function depends on its proper subcellular localization rather than the catalytic triad. Mechanistically, rather than eliminating Aβ, Yip7 binds intracellular Aβ42 to increase its neuronal retention, and this unexpectedly reduces Aβ42 toxicity to the organism. Finally, transcriptomics reveals that protection against Aβ42 toxicity by Yip7 is associated with selective suppression of Aβ-upregulated genes including those codingribosomal proteins and molecular chaperones for protein folding. Together, these findings introduce a novel concept that intracellular sequestration of Aβ can be explored to mitigate its neurotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.